Abstract Details

Title Seasonal Variations in MOG Antibody-Associated Disease: A Big Data Analysis from a Large Neuroimmunology Laboratory Database

Topic Autoimmune Neurology

Presentation(s) P7 - Poster Session 7 (5:00 PM-6:00 PM)

Poster/Presentation
Number 8-003

Objective

This study aimed to investigate the impact of seasonality on myelin oligodendrocyte glycoprotein (MOG)-IgG positivity rates, disease onset, and attacks of MOG antibody-associated disease (MOGAD).

Background

Studies on seasonal variation in MOG-IgG positivity, disease onset, and attacks of MOGAD are limited.

Design/Methods

This retrospective study firstly utilized big data from the Mayo Clinic Neuroimmunology Laboratory, where MOG-IgG sera were tested using a live cell-based assay from July 2014 to April 2024. Secondly, we reviewed the medical records of MOGAD patients from Mayo Clinic and external collaborations. The month of testing in the laboratory cohort and the month of disease onset and attacks in the clinical cohort were recorded.

Results

Among 90,094 patient sera tested for MOG-IgG, the highest proportion of MOG-IgG positivity was in winter (7.4%, 1,762/23,809), while the lowest was in summer (6.6%, 1,500/22,895;p=0.003). January had the highest rate (7.5%, 586/7,812), whereas July was the lowest (6.2%, 451/7,220;p=0.072). Similarly, the frequency of high-titer MOG-IgG (≥1:1,000) was highest in winter (2.3%, 547/23,809) and lowest in summer (1.7%, 390/22,895;p<0.001). December had the highest rate of high-titer cases (2.3%, 182/7,857), while July had the lowest (1.5%, 108/7,220;p=0.002).

Among 431 patients with available clinical data, disease onset was most frequent in winter (31.3%, 135/431) and least common in summer (20.6%, 89/431;p=0.003). January had the highest number of onset cases (14.8%, 64/431), while July had the fewest (6.7%, 29/431;p<0.001). Similarly, of the 994 recorded attacks, the highest frequency occurred in winter (30.5%, 303/994), with the lowest in summer (22.2%, 221/994;p<0.001). January had the most attacks (14%, 139/994), while July had the fewest (7.0%, 70/994;p<0.001).

Conclusions

This study found increased MOG-IgG positivity, disease onset, and disease activity during winter, particularly in January. Further investigation is needed to understand the mechanisms behind this seasonal pattern and its implications for patient management.

Authors/Disclosures
Nisa Vorasoot, MD PRESENTER	Dr. Vorasoot has nothing to disclose.
Matthew Edmond	Mr. Edmond has nothing to disclose.
Laura Cacciaguerra, MD, PhD (Mayo Clinic)	Dr. Cacciaguerra has nothing to disclose.
John Chen	John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. John Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology)	Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic)	The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Merck. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology that is relevant to AAN interests or activities.

��ɫ��

��ɫ��